狼疮肾炎持续完全肾脏缓解的预测因素与长期影响:中位10年随访
该研究纳入142例活检证实的狼疮肾炎起始队列患者,中位随访121个月,评估持续完全肾脏缓解(sCRR)的患病率、预测因素及长期结局。结果显示83%患者达到≥12个月sCRR,sCRR持续时间而非仅达到sCRR可降低eGFR下降≥30%、ESKD/死亡复合结局及疾病损伤累积风险。
要点
- 持续使用羟氯喹、基线非肾病性蛋白尿及III型vs IV型狼疮肾炎与更早达到sCRR相关。
- sCRR每增加1年,可降低eGFR下降≥30%和ESKD/死亡复合结局风险。
- sCRR≥4年可保护长期随访患者免于严重肾功能下降、ESKD/死亡及损伤累积。
核心结论
- 持续使用羟氯喹、基线非肾病性蛋白尿及III型vs IV型狼疮肾炎与更早达到sCRR相关。
- sCRR≥4年可降低eGFR下降≥30%、ESKD/死亡复合结局及损伤累积风险。
研究设计与样本
- 来自两个学术中心的142例活检证实的狼疮肾炎起始队列患者,中位随访121个月。
- 评估sCRR≥12个月的患病率及sCRR持续时间对肾脏复发、严重肾功能下降(较基线eGFR下降≥30%)、ESKD/死亡复合结局及疾病损伤的影响。
- 采用线性、逻辑和Cox回归模型分析数据。
主要发现
- 83%患者达到≥12个月sCRR,56.3%达到≥5年,20.4%达到≥10年。
- 持续使用羟氯喹(校正HR:1.86,P=0.004)、基线非肾病性蛋白尿(校正HR:1.71,P=0.016)及III型vs IV型狼疮肾炎(HR:1.89,P=0.018)与更早达到sCRR相关。
- sCRR后5年和10年肾脏复发风险随CRR每增加1年而降低。
- sCRR持续时间而非仅达到sCRR可降低eGFR下降≥30%风险(校正OR:0.81/年,P=0.015)和ESKD/死亡复合结局风险(校正HR:0.75/年,P=0.001)。
- sCRR≥12个月可防止损伤累积(校正β系数=-1.17,P<0.001)。
临床怎么用
- 对狼疮肾炎患者应重视持续使用羟氯喹以促进早期达到sCRR。
- 临床应关注sCRR的持续时间,维持sCRR≥4年以降低长期肾脏不良结局和损伤累积风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Complete renal response (CRR) is a primary goal in lupus nephritis (LN) management. We examined the prevalence and predictors of sustained CRR (sCRR) and long-term outcomes. METHODS: We included 142 inception cohort patients with biopsy-proven LN from two academic centres. We assessed the prevalence of sCRR achievement for ≥12 months and the impact of sCRR duration on renal flares, severe kidney function decline (≥30% eGFR decline compared with baseline), a composite end-stage kidney disease (ESKD) or death outcome, and disease damage. We analysed data over a median 121-month follow-up, using linear, logistic and Cox regression models. RESULTS: A total of 83% of patients achieved sCRR for ≥12 months, 56.3% for ≥5 years and 20.4% for ≥10 years. Persistent hydroxychloroquine use (adjusted HR: 1.86, P = 0.004), non-nephrotic baseline proteinuria (adjusted HR: 1.71, P = 0.016) and class III vs class IV LN (HR: 1.89, P = 0.018) were associated with earlier sCRR achievement. The 5- and 10-year post-sCRR risks for renal flares decreased for every additional year on CRR. sCRR duration rather than its mere achievement reduced the risk of ≥30% eGFR decline (adjusted OR: 0.81/year, P = 0.015) and composite ESKD/death (adjusted HR: 0.75/year, P = 0.001). sCRR ≥ 12 months protected against damage accrual (adjusted β-coef=-1.17, P < 0.001). Among those with ≥100-month follow-up, sCRR ≥ 4 years protected against severe kidney function decline (adjusted OR: 0.10, P = 0.005), ESKD/death (adjusted HR: 0.11, P = 0.043) and damage accrual (adjusted β-coef=-0.81, P = 0.012). CONCLUSION: Persistent hydroxychloroquine, non-nephrotic baseline proteinuria and class III vs IV are associated with earlier sCRR. sCRR ≥4 years protects against ≥30% eGFR decline, composite ESKD/death and damage.
引用
- Michelakis IE, Kapsia E, Boletis JN, et al. Predictors and long-term impact of sustained complete renal response in lupus nephritis patients over a median 10-year follow-up. Rheumatology (Oxford). 2026. PMID: 41390925. doi:10.1093/rheumatology/keaf677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。